Olympus launched HANAROSTENT Esophagus TTS Stent

HANAROSTENT Esophagus TTS stent

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, launched HANAROSTENT Esophagus TTS self-expanding metal stents (SEMS) made by M.I. Tech and distributed exclusively through Olympus in the U.S.

The Through-the-Scope (TTS) esophageal stent, the newest addition to the Olympus self-expanding stent portfolio, helps to achieve luminal patency in a variety of clinical applications and is designed for use in the palliative treatment of esophageal stricture and/or trachea-esophageal fistula caused by malignant tumors. The stent offers a fully covered or partially covered option.

Dr. Sandeep Patel, Gastroenterologist, UT Health San Antonio said: “From the first cases in which I’ve used it, I found the HANAROSTENT Esophagus TTS stent to effectively palliate the symptoms of our patients with advanced esophageal cancer. The hook-cross nitinol design of the TTS stents allows for accurate and efficient placement with increased patient comfort.”

Pre-loaded into the delivery system, the HANAROSTENT Esophagus TTS fits down the working channel of a standard therapeutic gastroscope and is deployed for placement in the esophagus. The hook-and-cross nitinol design, unique to HANAROSTENT products, was designed with patient comfort in mind and enables optimal radial and axial force allowing for the flexibility to conform to a patient’s anatomy and precisely target the stricture.

Unlike over-the-wire esophageal stents, the new 10.5F HANAROSTENT Esophagus TTS allows for accurate and easy esophageal stenting under direct endoscopic visualization. 

Kevin Mancini, Vice President for Endoscopy, Olympus America Inc. said: “We are pleased with the positive clinical feedback we have received from our trusted physician customers since our limited launch of HANAROSTENT Esophagus TTS in July. We are confident the HANAROSTENT Esophagus TTS will help our physician customers address quality of life issues in patients suffering from advanced gastrointestinal disease.”

Jin-Hyung Park, CEO, M.I. Tech said: “Through our valued partnership with Olympus, the HANAROSTENT Esophagus TTS is the sixth stent successfully launched in the U.S. market in the past two years. We are thrilled to continue expanding capabilities of physicians in the U.S. and across the world, through the combination of a line of unparalleled stents and the trusted Olympus brand.”